Safety of Pediatric COVID-19 Vaccination

Completed

Conditions studied: Pain, Injection Site Reaction, Adverse Drug Event

In brief

This is a prospective, observational study. During the study, children and adolescents (ages ≥ 5 to \< 16) will be followed post administration of mRNA COVID-19 vaccines. Injection site (local), systemic reaction, and unsolicited adverse event data will be assessed on vaccination day and during the 7 days following each vaccination using either identical web-based or paper diaries, depending on study participant preference. At Duke University, Cincinnati's Children Hospital, and Kaiser Permanente Northern California, serum samples will be collected for optional assessment of antibody titers to COVID-19. Each participant who opts in will have baseline (within 3 days of vaccination) serologies obtained and immunogenicity assessment at 28 (+7) days after each dose. All participants will be followed for 180 days after dose 2 for serious adverse events and adverse events of special interest.

Key facts

Study ID

NCT05157191

Run by

Duke University

People needed

299

Starts

2022-04-06

Expected to finish

2023-10-27

Last updated by the study team

2026-07-01

Who can join

Age: 5 and older, up to 15. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Children ≥ 5 years to < 16 years of age
• Receiving first dose or a booster dose of a U.S authorized or approved and recommended COVID-19 vaccine per standard of care
• Parent/legal authorized representative (LAR) willing to provide written informed consent per local IRB requirements
• Participant willing to provide assent per local IRB requirements
• Intention of being available for entire study period and complete all relevant study procedures, including follow-up phone calls
• English or Spanish literate.

You may not qualify if…

• Current or planned participation in any clinical trial with an investigational product during the study period.*
• Per protocol, co-enrollment in observational or behavioral intervention studies are permitted at any time. An investigational product or behavioral intervention permitted at any time. An investigational product may be permitted for therapy of an illness condition that occurs during the study period (e.g., COVID-19 illness)
• Any condition, which, in the opinion of the investigators, may pose a health risk to the subject or interfere with the evaluation of the study objectives.
• Anyone who is a relative of any research study personnel or is an employee supervised by study staff.

Where it is running

• Kaiser Permanente Northern California — Oakland, California, United States
• Centers for Disease Control and Prevention — Atlanta, Georgia, United States
• Columbia University — New York, New York, United States
• Duke University — Durham, North Carolina, United States
• Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.